Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus
about
Structural and Computational Biology in the Design of Immunogenic Vaccine AntigensEmerging Vaccine TechnologiesA Blueprint for HIV Vaccine DiscoveryA New Scientific Paradigm may be Needed to Finally Develop an HIV VaccineStructure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial VirusStructure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing AntibodyStructure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial VirusProof of principle for epitope-focused vaccine designReverse vaccinology 2.0: Human immunology instructs vaccine antigen designProtein Crystallography in Vaccine Research and DevelopmentDengue: knowledge gaps, unmet needs, and research prioritiesImmunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.Computational tools for epitope vaccine design and evaluationTransplanting supersites of HIV-1 vulnerability.Options and obstacles for designing a universal influenza vaccinePeptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 moleculePalivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.Future opportunities for passive immunity against viral diseases.Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platformComputational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffoldingA Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSVBiomimetic monolayer-protected gold nanoparticles for immunorecognitionHigh Resolution Mapping of Bactericidal Monoclonal Antibody Binding Epitopes on Staphylococcus aureus Antigen MntC.Adversomics: a new paradigm for vaccine safety and design.Addressing viral resistance through vaccinesPrefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera.A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin.Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.Advances in antiviral vaccine development.Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.Respiratory syncytial virus: current progress in vaccine development.Vaccine design: emerging concepts and renewed optimism.Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.Recent advances in the development of subunit-based RSV vaccines.CD4+ T cells support establishment of RSV-specific IgG and IgA antibody secreting cells in the upper and lower murine respiratory tract following RSV infection.Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection.Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein.Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.
P2860
Q26777382-2E3FED6F-A575-4249-860E-DBFA9C34F73DQ26783764-B2C1E940-D26D-483D-ADF8-CB747C3D04E0Q26829865-04AFFA36-86CB-4BA0-8A3A-D5ED98DB6AB6Q26830360-9AC6BFE8-B451-4018-B6BD-5C93A125AB9CQ27333522-4B3FCDCB-5360-41D6-BEDF-08334E95DF66Q27677570-0FFBF654-FEEF-4E38-96FA-66E007D85580Q27680499-E0D0A9E1-3BC3-4532-96E9-C23617FBE1E5Q27681593-E0D21C77-9405-47A2-A06A-E082ED6B0BBFQ28075274-898E849B-9DF7-41AC-AEE4-C233C019C351Q28087528-DF803FF7-7BB8-4216-AE0F-DC4D1EF02336Q28729764-5924CDAC-C582-4D71-9138-04CB8E0B82CFQ30353709-9DD7F53F-4C25-48FB-9055-004A74BFBD8FQ30373339-519C51FF-994F-4DDF-A8EA-2DCB297BE9BFQ33854841-DCC934E5-584D-4689-9B4A-4565D3AC1600Q34102290-CCBA271C-AFC2-453A-8AEC-CE97EEB49EC1Q35488811-BF465442-8357-4D03-9BAD-97BC6532DD64Q35535626-61F9C00C-49B8-4EAC-BAE1-EBB6E20632D8Q35557110-34BD2B83-D882-4696-8A7C-012770251B5BQ35591551-6C2D3D8A-DD51-4A01-B296-D27FFD555E83Q35624791-000FBAE7-9227-42BF-AC0D-0CDD11E5A246Q35942829-8A8E3661-15A9-4CB3-AA34-5C8A38CBF727Q36029158-A751FF80-EE41-4C5F-BDD3-3A8FFE772A63Q36035568-CA094DFB-E737-4F84-825E-D544D483090FQ36149696-E7B80618-7CC1-4C33-A3C8-0E1A1008EB64Q36242667-7B210B1B-2F1D-4E69-859C-F712A04B64A5Q36304783-4FF9D462-FDD5-4400-ACA7-9FFE16672563Q36353767-CC5E0652-C8D5-45F0-B8F8-522E8BAC7F32Q36363177-96685431-1742-4E86-90BC-8837081567CFQ36693991-3C9646B8-75DD-4203-820F-C94EFB033BB8Q37292398-4E99C8CA-D6D8-47A8-964B-68B16F6B56B8Q37536191-138231FA-45AA-4092-9123-FBD2088BA762Q38079432-A6C5807B-E8BB-4C1D-B6FF-2E91786142C2Q38087785-BBE9AA66-9E56-460D-9009-8EC99AF081C5Q38394731-949CD736-85B1-4608-93EB-0150B69E98D2Q38617302-CCBB967F-0FA4-4D82-AC72-2FAC2977251BQ38836417-A6FC2BD1-5174-4D72-95F1-706214E34584Q39170404-AFB990AE-30B0-450A-9631-3963792264CFQ40046506-1DEF2787-ECA3-44E6-AEB9-8A97E3233E12Q40047887-A7A94130-9712-48F3-912D-395D007BA587Q40565908-2DC747FE-3F74-44D1-A67D-853DC14BEED1
P2860
Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Design and Characterization of ...... om Respiratory Syncytial Virus
@ast
Design and Characterization of ...... om Respiratory Syncytial Virus
@en
Design and Characterization of ...... om Respiratory Syncytial Virus
@nl
type
label
Design and Characterization of ...... om Respiratory Syncytial Virus
@ast
Design and Characterization of ...... om Respiratory Syncytial Virus
@en
Design and Characterization of ...... om Respiratory Syncytial Virus
@nl
prefLabel
Design and Characterization of ...... om Respiratory Syncytial Virus
@ast
Design and Characterization of ...... om Respiratory Syncytial Virus
@en
Design and Characterization of ...... om Respiratory Syncytial Virus
@nl
P2093
P2860
P3181
P1476
Design and Characterization of ...... om Respiratory Syncytial Virus
@en
P2093
Bruno E Correia
Jason S McLellan
Peter D Kwong
William R Schief
Yongping Yang
P2860
P304
P3181
P356
10.1016/J.JMB.2011.04.044
P407
P577
2011-06-24T00:00:00Z